These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22326647)

  • 21. [Intensive search for agents that knock out tumor growth].
    Ostman A
    Lakartidningen; 2010 Apr 21-27; 107(16):1066-70. PubMed ID: 20476703
    [No Abstract]   [Full Text] [Related]  

  • 22. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
    Lippert TH; Ruoff HJ; Volm M
    Arzneimittelforschung; 2008; 58(6):261-4. PubMed ID: 18677966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
    Parkinson DR; Johnson BE; Sledge GW
    Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeted and personalized therapy for cancer: theory and practice in China.
    Liu Q; Zhang X; Zeng Y
    Sci China Life Sci; 2011 Dec; 54(12):1081-4. PubMed ID: 22227898
    [No Abstract]   [Full Text] [Related]  

  • 26. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription factors and drug resistance.
    Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
    Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refocusing the war on cancer: the critical role of personalized treatment.
    Potti A; Schilsky RL; Nevins JR
    Sci Transl Med; 2010 Apr; 2(28):28cm13. PubMed ID: 20410527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
    Xu W; Neckers L
    Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
    [No Abstract]   [Full Text] [Related]  

  • 30. [Targeted drugs a chance for a better cure].
    Bergh J; Jonsson B
    Lakartidningen; 2010 Apr 21-27; 107(16):1071-4. PubMed ID: 20476704
    [No Abstract]   [Full Text] [Related]  

  • 31. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calculated resistance in cancer.
    Sawyers CL
    Nat Med; 2005 Aug; 11(8):824-5. PubMed ID: 16079872
    [No Abstract]   [Full Text] [Related]  

  • 33. Emerging strategies for ErbB ligand-based targeted therapy for cancer.
    Tsujioka H; Yotsumoto F; Shirota K; Horiuchi S; Yoshizato T; Kuroki M; Miyamoto S
    Anticancer Res; 2010 Aug; 30(8):3107-12. PubMed ID: 20871027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Individualized medicine between expectations and reality].
    Hinneburg I
    Med Monatsschr Pharm; 2011 Jun; 34(6):212-4. PubMed ID: 21812253
    [No Abstract]   [Full Text] [Related]  

  • 37. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
    Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
    Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Future drug treatment against cancer viewed from current statistical data].
    Nishiyama M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():16-22. PubMed ID: 25831718
    [No Abstract]   [Full Text] [Related]  

  • 39. Breakthrough in cancer treatment.
    van der Linde I
    S Afr Med J; 1998 Jul; 88(7):813. PubMed ID: 9698707
    [No Abstract]   [Full Text] [Related]  

  • 40. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
    Murph MM; Smith DL; Hennessy B; Lu Y; Joy C; Coombes KR; Mills GB
    Adv Exp Med Biol; 2008; 622():183-95. PubMed ID: 18546628
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.